Earum Pharmaceuticals Limited was originally incorporated as a private limited company with the name 'Earum Pharmaceuticals Private Limited' onJuly 26, 2012. Further, pursuant to Special Resolution passed by the shareholders at the Extra Ordinary General Meeting held on January 10, 2019, the company was converted into a Public Limited Company and consequently the name of the Company was changed from 'Earum Pharmaceuticals Private Limited' to 'Earum Pharmaceuticals Limited' on January 23, 2019. Mr. Bhumishth Narendrabhai Patel and Mrs. Payal Bhumishth Patel were the initial subscribers to Memorandum of Association of the Company. The Company is engaged in the pharmaceutical business involving marketing, trading and distribution of wide range of pharmaceutical formulation products such as anti-biotic drugs, anti-malarial drugs, anti-allergic & anti cold drugs, analgesic/ anti-pyretic & anti inflammatory drugs, dermatology products, cerebral activator drugs, neurological drugs, gastro intestinal drugs, steroids, gynecology drugs, calcium, multivitamins, anti-oxidants and injections. At present, the company offers around 125 pharmaceutical formulation products, of which around 24 products are marketed under its own brand name, the manufacturing of which is outsourced by the company to third parties. Apart from pharmaceutical formulation products, the company also deals in trading of active pharmaceutical ingredients (API's) such as Levofloxacin Hemihdrate IP Albendazol IP, Amoxicillin Trihydrate IP etc.